Lataa...
Checking up on checkpoint inhibitors
In this issue of Blood, Haverkos et al present timely and compelling data revealing both the opportunity and serious hazards incurred with the use of programmed death 1 (PD-1) pathway blockade after allogeneic hematopoietic cell transplant (allo-HCT) in relapsed lymphoma patients.(1)
Tallennettuna:
| Julkaisussa: | Blood |
|---|---|
| Päätekijät: | , |
| Aineistotyyppi: | Artigo |
| Kieli: | Inglês |
| Julkaistu: |
American Society of Hematology
2017
|
| Aiheet: | |
| Linkit: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5510793/ https://ncbi.nlm.nih.gov/pubmed/28705859 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood-2017-05-783696 |
| Tagit: |
Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!
|